Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus oral etoposide for previously treated triple-negative breast cancer
ChiCTR1800018497Phase 2Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Sep 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and etoposide in triple-negative breast cancer (TNBC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Size of the lesions. Started Sep 2018; status: recruiting.
02
Drugs
Rivoceranibetoposide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR1800018497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018497.